Author's Reply to Comments to: Long-Term Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Diabetic Macular Edema

Abstract

Get full access to this article

View all access options for this article.

References

Călugăru

Comments to: Long-term efficacy and safety of intravitreal dexamethasone implant for the treatment of diabetic macular edema. Eur J Ophthalmol doi: 10.5301/ejo.5000869. [Epub ahead of print].

Sophie

Campochiaro

Predictors of Functional and Anatomic Outcomes in Patients with Diabetic Macular Edema Treated with Ranibizumab. Ophthalmology. 2015;122(7):1395–1401

Mitchell

Bandello

Schmidt-Erfurth

et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology. 2011;118(4):615–625

Gillies

Lim

Campain

A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology. 2014;121(12):2473–2481

Escobar-Barranco

Pina-Marín

Fernández-Bonet

Fernan- dez-Bonet M: Dexamethasone implants in patients with naive or refractory diffuse dia- betic macular edema. Ophthalmologica. 2015;2333-4176–185

Bellocq

Pierre-Kahn

Matonti

Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. Br J Ophthalmol. 2016 May 17. doi: 10.1136/bjophthalmol-2016-308544. [Epub ahead of print].